Bausch + Lomb’s ELIOS Glaucoma System Hits Key Efficacy Marks in 24‑Month U.S. Trial
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Bausch + Lomb Corporation ( (BLCO) ).
Bausch + Lomb reported positive 24‑month results from a pivotal U.S. clinical trial of its ELIOS System, an implant‑free, minimally invasive excimer laser procedure designed to reduce intraocular pressure in patients with mild to moderate open‑angle glaucoma undergoing cataract surgery. The system, already CE marked in Europe but still under development in the U.S., met both primary effectiveness endpoints with 76% of patients achieving at least a 20% reduction in unmedicated diurnal intraocular pressure and 82% remaining medication‑free at 23 months, while maintaining a safety profile comparable to cataract surgery alone.
The strong topline data bolster Bausch + Lomb’s position in the fast‑growing minimally invasive glaucoma surgery segment and support the potential U.S. adoption of ELIOS as an alternative to more invasive procedures such as trabeculectomy and tube shunts. The company plans to present detailed findings at future medical meetings and in a peer‑reviewed journal, which could help build clinical confidence and pave the way for future regulatory submissions, potentially expanding its surgical portfolio and strengthening its competitiveness in glaucoma treatment.
The most recent analyst rating on (BLCO) stock is a Buy with a $17.50 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
The score is most constrained by weak financial performance—multi-year net losses and negative free cash flow—despite solid revenue growth and a supportive balance sheet in the latest period. Offsetting this, the earnings call was strong with clear 2026 guidance for improved margins and EBITDA growth, and the technical setup is constructive with the stock trending above key moving averages. Valuation is held back by negative earnings and no stated dividend support.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a global eye health company that develops and markets contact lenses, prescription ophthalmic drugs, over-the-counter eye care products and surgical devices. With a focus on innovation in vision care and ophthalmic surgery, the company targets patients with a broad range of eye conditions, including glaucoma and cataracts, across key markets in North America, Europe and beyond.
Average Trading Volume: 398,220
Technical Sentiment Signal: Sell
Current Market Cap: $5.57B
Find detailed analytics on BLCO stock on TipRanks’ Stock Analysis page.
